Researchers reported an mRNA‑LNP approach encoding anti‑PD‑L1 nanobodies that controlled tumor growth in preclinical colorectal cancer models. The study demonstrated delivery of single‑domain antibody constructs via lipid nanoparticles to generate intratumoral blockade of PD‑L1 and elicit anti‑tumor responses in mice. Published in eGastroenterology, the work links mRNA payload flexibility with the manufacturing and dosing advantages of nanobody formats, suggesting a path for localized immunotherapy that avoids systemic exposure limits of full‑length antibodies. The results support further optimization toward clinical translation for solid tumors.